What Does the $2T Stimulus Bill Mean for Medtech?

 The United States International Trade Commission (USITC) released its highly anticipated report,“COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TRIPS Agreement Flexibilities” on October 17. Evidence presented in the 496-page report supports AdvaMed®’s position that there is no justification for the World Trade Organization (WTO) to waive intellectual property protection for products used to treat or diagnose COVID-19.

Cary Vance, President and CEO of Titan Medical, joined AdvaMed®’s Scott Whitaker on the Medtech POV podcast to share his experience leading a small medical device company through the regulatory process as they transition from design to manufacturing.

This white paper from IQVIA – an associate member of AdvaMed® – discusses how global markets and specific therapeutic areas are poised for growth over the next decade.

This report outlines a key data-driven summary of the U.S. COVID testing supply.

Mick Farrell, CEO of ResMed, joined Scott Whitaker on the Medtech POV podcast to explain what motivates him to serve patients and his community.

Mick Farrell, ResMed CEO and member of the AdvaMed® board of directors, joined AdvaMed®’s Scott Whitaker on the Medtech POV podcast to discuss how an agile company with skilled staff and a clear mission can pivot sharply as the market demands, from scaling up ventilator production at the outset of the COVID-19 pandemic to informing semiconductor chips manufacturers of their product’s critical importance to the medical technology industry.

This report examines cumulative data from the first two years of the COVID Test Registry to demonstrate the mobilization of the diagnostics industry over the course of the pandemic.

Today, AdvaMed® President and CEO Scott Whitaker issued a statement following the White House’s announcement that the federal government’s COVID-19 response would be reduced in the coming weeks without additional funding from Congress: